Is CERS or XRAY more profitable?

Cerus has a net margin of -4.41% compared to DENTSPLY SIRONA's net margin of -17.06%. DENTSPLY SIRONA's return on equity of 18.83% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Cerus -4.41% -15.18% -4.38% DENTSPLY SIRONA -17.06% 18.83% 5.13%

Does the media prefer CERS or XRAY?

In the previous week, Cerus and Cerus both had 3 articles in the media. DENTSPLY SIRONA's average media sentiment score of 1.14 beat Cerus' score of 0.54 indicating that DENTSPLY SIRONA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DENTSPLY SIRONA 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, CERS or NEOG?

Cerus has higher earnings, but lower revenue than Neogen. Cerus is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cerus $206.13M 2.84 -$15.63M -$0.05 N/A Neogen $894.66M 2.33 -$1.09B -$2.80 N/A

Is CERS or NEOG more profitable?

Cerus has a net margin of -4.41% compared to Neogen's net margin of -69.93%. Neogen's return on equity of 2.35% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Cerus -4.41% -15.18% -4.38% Neogen -69.93% 2.35% 1.46%

Does the media prefer CERS or NEOG?

In the previous week, Cerus had 1 more articles in the media than Neogen. MarketBeat recorded 3 mentions for Cerus and 2 mentions for Neogen. Neogen's average media sentiment score of 0.60 beat Cerus' score of 0.54 indicating that Neogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CERS or STAA more profitable?

Cerus has a net margin of -4.41% compared to STAAR Surgical's net margin of -7.24%. STAAR Surgical's return on equity of 3.31% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Cerus -4.41% -15.18% -4.38% STAAR Surgical -7.24% 3.31% 2.55%

Does the media refer more to CERS or STAA?

In the previous week, STAAR Surgical had 2 more articles in the media than Cerus. MarketBeat recorded 5 mentions for STAAR Surgical and 3 mentions for Cerus. Cerus' average media sentiment score of 0.54 beat STAAR Surgical's score of 0.54 indicating that Cerus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive STAAR Surgical 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CERS or QDEL more profitable?

Cerus has a net margin of -4.41% compared to QuidelOrtho's net margin of -45.57%. QuidelOrtho's return on equity of 4.25% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Cerus -4.41% -15.18% -4.38% QuidelOrtho -45.57% 4.25% 1.56%

Does the media refer more to CERS or QDEL?

In the previous week, QuidelOrtho had 5 more articles in the media than Cerus. MarketBeat recorded 8 mentions for QuidelOrtho and 3 mentions for Cerus. Cerus' average media sentiment score of 0.54 beat QuidelOrtho's score of 0.20 indicating that Cerus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive QuidelOrtho 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CERS or OSUR more profitable?

Cerus has a net margin of -4.41% compared to OraSure Technologies' net margin of -66.42%. Cerus' return on equity of -15.18% beat OraSure Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Cerus -4.41% -15.18% -4.38% OraSure Technologies -66.42% -18.57% -15.71%

Does the media favor CERS or OSUR?

In the previous week, Cerus had 1 more articles in the media than OraSure Technologies. MarketBeat recorded 3 mentions for Cerus and 2 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 0.93 beat Cerus' score of 0.54 indicating that OraSure Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OraSure Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cerus (CERS) Competitors

$2.92 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$2.93 +0.01 (+0.34%)

As of 06/26/2026 07:10 PM Eastern

Compare

CERS vs. XRAY, NEOG, STAA, QDEL, and OSUR

Should you buy Cerus stock or one of its competitors? MarketBeat compares Cerus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cerus include DENTSPLY SIRONA (XRAY), Neogen (NEOG), STAAR Surgical (STAA), QuidelOrtho (QDEL), and OraSure Technologies (OSUR). These companies are all part of the "health care supplies" industry.

How does Cerus compare to DENTSPLY SIRONA?

Cerus (NASDAQ:CERS) and DENTSPLY SIRONA (NASDAQ:XRAY) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

78.4% of Cerus shares are owned by institutional investors. Comparatively, 95.7% of DENTSPLY SIRONA shares are owned by institutional investors. 3.4% of Cerus shares are owned by insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Cerus and Cerus both had 3 articles in the media. DENTSPLY SIRONA's average media sentiment score of 1.14 beat Cerus' score of 0.54 indicating that DENTSPLY SIRONA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DENTSPLY SIRONA	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cerus presently has a consensus target price of $4.00, suggesting a potential upside of 36.99%. DENTSPLY SIRONA has a consensus target price of $13.55, suggesting a potential upside of 23.03%. Given Cerus' stronger consensus rating and higher probable upside, research analysts clearly believe Cerus is more favorable than DENTSPLY SIRONA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
DENTSPLY SIRONA	3 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cerus has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market. Comparatively, DENTSPLY SIRONA has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

Cerus has higher earnings, but lower revenue than DENTSPLY SIRONA. Cerus is trading at a lower price-to-earnings ratio than DENTSPLY SIRONA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.84	-$15.63M	-$0.05	N/A
DENTSPLY SIRONA	$3.68B	0.60	-$598M	-$3.15	N/A

Cerus has a net margin of -4.41% compared to DENTSPLY SIRONA's net margin of -17.06%. DENTSPLY SIRONA's return on equity of 18.83% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-4.41%	-15.18%	-4.38%
DENTSPLY SIRONA	-17.06%	18.83%	5.13%

Summary

Cerus beats DENTSPLY SIRONA on 8 of the 15 factors compared between the two stocks.

How does Cerus compare to Neogen?

Cerus (NASDAQ:CERS) and Neogen (NASDAQ:NEOG) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Cerus had 1 more articles in the media than Neogen. MarketBeat recorded 3 mentions for Cerus and 2 mentions for Neogen. Neogen's average media sentiment score of 0.60 beat Cerus' score of 0.54 indicating that Neogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cerus presently has a consensus price target of $4.00, suggesting a potential upside of 36.99%. Neogen has a consensus price target of $10.67, suggesting a potential upside of 11.34%. Given Cerus' stronger consensus rating and higher probable upside, equities analysts clearly believe Cerus is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Cerus has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market. Comparatively, Neogen has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market.

Cerus has higher earnings, but lower revenue than Neogen. Cerus is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.84	-$15.63M	-$0.05	N/A
Neogen	$894.66M	2.33	-$1.09B	-$2.80	N/A

78.4% of Cerus shares are held by institutional investors. Comparatively, 96.7% of Neogen shares are held by institutional investors. 3.4% of Cerus shares are held by insiders. Comparatively, 0.6% of Neogen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cerus has a net margin of -4.41% compared to Neogen's net margin of -69.93%. Neogen's return on equity of 2.35% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-4.41%	-15.18%	-4.38%
Neogen	-69.93%	2.35%	1.46%

Summary

Cerus beats Neogen on 8 of the 15 factors compared between the two stocks.

How does Cerus compare to STAAR Surgical?

Cerus (NASDAQ:CERS) and STAAR Surgical (NASDAQ:STAA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

In the previous week, STAAR Surgical had 2 more articles in the media than Cerus. MarketBeat recorded 5 mentions for STAAR Surgical and 3 mentions for Cerus. Cerus' average media sentiment score of 0.54 beat STAAR Surgical's score of 0.54 indicating that Cerus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
STAAR Surgical	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cerus has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, STAAR Surgical has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

Cerus currently has a consensus target price of $4.00, indicating a potential upside of 36.99%. STAAR Surgical has a consensus target price of $27.81, indicating a potential downside of 5.04%. Given Cerus' stronger consensus rating and higher possible upside, research analysts plainly believe Cerus is more favorable than STAAR Surgical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
STAAR Surgical	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09

Cerus has higher earnings, but lower revenue than STAAR Surgical. STAAR Surgical is trading at a lower price-to-earnings ratio than Cerus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.84	-$15.63M	-$0.05	N/A
STAAR Surgical	$239.44M	6.09	-$80.45M	-$0.43	N/A

78.4% of Cerus shares are owned by institutional investors. Comparatively, 96.7% of STAAR Surgical shares are owned by institutional investors. 3.4% of Cerus shares are owned by insiders. Comparatively, 39.9% of STAAR Surgical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cerus has a net margin of -4.41% compared to STAAR Surgical's net margin of -7.24%. STAAR Surgical's return on equity of 3.31% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-4.41%	-15.18%	-4.38%
STAAR Surgical	-7.24%	3.31%	2.55%

Summary

Cerus and STAAR Surgical tied by winning 8 of the 16 factors compared between the two stocks.

How does Cerus compare to QuidelOrtho?

Cerus (NASDAQ:CERS) and QuidelOrtho (NASDAQ:QDEL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Cerus has a net margin of -4.41% compared to QuidelOrtho's net margin of -45.57%. QuidelOrtho's return on equity of 4.25% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-4.41%	-15.18%	-4.38%
QuidelOrtho	-45.57%	4.25%	1.56%

In the previous week, QuidelOrtho had 5 more articles in the media than Cerus. MarketBeat recorded 8 mentions for QuidelOrtho and 3 mentions for Cerus. Cerus' average media sentiment score of 0.54 beat QuidelOrtho's score of 0.20 indicating that Cerus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
QuidelOrtho	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cerus has higher earnings, but lower revenue than QuidelOrtho. Cerus is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.84	-$15.63M	-$0.05	N/A
QuidelOrtho	$2.73B	0.34	-$1.13B	-$17.82	N/A

Cerus has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

78.4% of Cerus shares are owned by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are owned by institutional investors. 3.4% of Cerus shares are owned by insiders. Comparatively, 1.1% of QuidelOrtho shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cerus currently has a consensus target price of $4.00, suggesting a potential upside of 36.99%. QuidelOrtho has a consensus target price of $14.88, suggesting a potential upside of 7.87%. Given Cerus' stronger consensus rating and higher probable upside, equities analysts clearly believe Cerus is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
QuidelOrtho	2 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Cerus beats QuidelOrtho on 10 of the 16 factors compared between the two stocks.

How does Cerus compare to OraSure Technologies?

Cerus (NASDAQ:CERS) and OraSure Technologies (NASDAQ:OSUR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Cerus has a net margin of -4.41% compared to OraSure Technologies' net margin of -66.42%. Cerus' return on equity of -15.18% beat OraSure Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-4.41%	-15.18%	-4.38%
OraSure Technologies	-66.42%	-18.57%	-15.71%

In the previous week, Cerus had 1 more articles in the media than OraSure Technologies. MarketBeat recorded 3 mentions for Cerus and 2 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 0.93 beat Cerus' score of 0.54 indicating that OraSure Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OraSure Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.4% of Cerus shares are owned by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are owned by institutional investors. 3.4% of Cerus shares are owned by company insiders. Comparatively, 4.7% of OraSure Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Cerus has higher revenue and earnings than OraSure Technologies. Cerus is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.84	-$15.63M	-$0.05	N/A
OraSure Technologies	$115.02M	2.67	-$68.73M	-$1.04	N/A

Cerus presently has a consensus price target of $4.00, suggesting a potential upside of 36.99%. OraSure Technologies has a consensus price target of $3.00, suggesting a potential downside of 32.74%. Given Cerus' stronger consensus rating and higher probable upside, equities analysts clearly believe Cerus is more favorable than OraSure Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
OraSure Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Cerus has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market. Comparatively, OraSure Technologies has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market.

Summary

Cerus beats OraSure Technologies on 12 of the 16 factors compared between the two stocks.

Get Cerus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CERS vs. The Competition

Export

Metric	Cerus	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$585.08M	$8.70B	$7.03B	$12.19B
Dividend Yield	N/A	2.47%	2.66%	6.11%
P/E Ratio	-58.40	16.18	26.13	24.16
Price / Sales	2.84	7.29	555.66	102.83
Price / Cash	N/A	18.07	29.09	36.93
Price / Book	8.59	3.37	10.78	6.38
Net Income	-$15.63M	$226.25M	$3.58B	$337.00M
7 Day Performance	12.31%	2.11%	1.97%	-0.20%
1 Month Performance	-3.95%	-3.20%	-0.24%	-1.40%
1 Year Performance	105.63%	0.80%	34.39%	27.76%

Cerus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CERS Cerus	2.4356 of 5 stars	$2.92 flat	$4.00 +37.0%	+105.6%	$585.08M	$206.13M	N/A	290	Short Interest Increase Gap Down High Trading Volume
XRAY DENTSPLY SIRONA	4.5436 of 5 stars	$10.15 0.0%	$13.55 +33.5%	-30.9%	$2.03B	$3.68B	N/A	14,000
NEOG Neogen	1.3075 of 5 stars	$9.01 +1.0%	$10.67 +18.5%	+102.5%	$1.96B	$894.66M	N/A	2,110	News Coverage
STAA STAAR Surgical	1.8086 of 5 stars	$28.62 -0.7%	$27.81 -2.8%	+73.1%	$1.43B	$239.44M	N/A	1,211	News Coverage Analyst Upgrade
QDEL QuidelOrtho	2.1207 of 5 stars	$12.09 -2.3%	$14.88 +23.0%	-52.2%	$826.46M	$2.73B	N/A	6,500	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CERS) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cerus (CERS) Competitors

CERS vs. XRAY, NEOG, STAA, QDEL, and OSUR

How does Cerus compare to DENTSPLY SIRONA?

Summary

How does Cerus compare to Neogen?

Summary

How does Cerus compare to STAAR Surgical?

Summary

How does Cerus compare to QuidelOrtho?

Summary

How does Cerus compare to OraSure Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERS vs. The Competition

Cerus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cerus (CERS) Competitors

CERS vs. XRAY, NEOG, STAA, QDEL, and OSUR

How does Cerus compare to DENTSPLY SIRONA?

Do institutionals & insiders hold more shares of CERS or XRAY?

Does the media prefer CERS or XRAY?

Do analysts rate CERS or XRAY?

Which has more volatility and risk, CERS or XRAY?

Which has higher valuation & earnings, CERS or XRAY?

Is CERS or XRAY more profitable?

Summary

How does Cerus compare to Neogen?

Does the media prefer CERS or NEOG?

Do analysts prefer CERS or NEOG?

Which has more volatility & risk, CERS or NEOG?

Which has stronger earnings and valuation, CERS or NEOG?

Do insiders & institutionals have more ownership in CERS or NEOG?

Is CERS or NEOG more profitable?

Summary

How does Cerus compare to STAAR Surgical?

Does the media refer more to CERS or STAA?

Which has more risk & volatility, CERS or STAA?

Do analysts prefer CERS or STAA?

Which has stronger earnings and valuation, CERS or STAA?

Do insiders and institutionals have more ownership in CERS or STAA?

Is CERS or STAA more profitable?

Summary

How does Cerus compare to QuidelOrtho?

Is CERS or QDEL more profitable?

Does the media refer more to CERS or QDEL?

Which has preferable valuation & earnings, CERS or QDEL?

Which has more volatility and risk, CERS or QDEL?

Do institutionals & insiders hold more shares of CERS or QDEL?

Do analysts recommend CERS or QDEL?

Summary

How does Cerus compare to OraSure Technologies?

Is CERS or OSUR more profitable?

Does the media favor CERS or OSUR?

Do institutionals and insiders hold more shares of CERS or OSUR?

Which has stronger earnings & valuation, CERS or OSUR?

Do analysts rate CERS or OSUR?

Which has more volatility and risk, CERS or OSUR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERS vs. The Competition

Cerus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools